跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 103 条关于
“EMMI”
全部
103
临床试验
60
药物
16
机构
4
资讯
23
10个月前
Terray Therapeutics Achieves Drug Discovery Milestone with Bristol Myers Squibb Using AI-Native EMMI Platform
上个月
Epic Signals a Shift Toward Patient-Directed AI as EHR Giant Weighs Direct-to-Consumer Power
去年
Tirzepatide Shows 94% Risk Reduction in Type 2 Diabetes Progression Over Three Years
去年
Tirzepatide Shows Sustained Weight Loss and Reduces Type 2 Diabetes Risk in Obese, Pre-diabetic Individuals
去年
Tirzepatide Reduces Heart Failure Risk in HFpEF Patients with Obesity: SUMMIT Trial
去年
Tirzepatide Shows Promise in Phase III Trial for Heart Failure with Preserved Ejection Fraction
去年
Tirzepatide Reduces Heart Failure Risk by 38% in HFpEF Patients with Obesity
2年前
Tirzepatide Shows Promise in Reducing Diabetes Risk and Outperforming Insulin
2年前
Lilly's Once-Weekly Insulin Efsitora Shows Promise in Phase 3 Diabetes Trials
去年
Tirzepatide Demonstrates Superior Speed in Achieving Diabetes Control and Weight Loss Targets
第 1 页,共 3 页
上一页
下一页